RaQualia Pharma (TSE:4579) Beneish M-Score: -2.06 (As of Jul. 08, 2026)


TSE:4579 RaQualia Pharma Inc TSE:4579
57 GF Score
Price 円468.00
GF Value 円961.31
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma Beneish M-Score?

RaQualia Pharma TSE:4579 -2.70% 57 Beneish M-Score is -2.06 as of Jul. 08, 2026. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 822 Biotechnology companies, RaQualia Pharma ranks worse than 60.1% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.06 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for RaQualia Pharma's Beneish M-Score or its related term are showing as below:

TSE:4579' s Beneish M-Score Range Over the Past 10 Years
Min: -4.77   Med: -2.03   Max: 440.44
Current: -2.06

During the past 13 years, the highest Beneish M-Score of RaQualia Pharma was 440.44. The lowest was -4.77. And the median was -2.03.


RaQualia Pharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Beneish M-Score Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.12 -3.60 -2.00 -2.41 -0.25

RaQualia Pharma Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.41 -2.20 -3.03 -0.25 -2.06

TSE:4579 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, RaQualia Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaQualia Pharma Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where RaQualia Pharma's Beneish M-Score falls into.


TSE:4579
57GF Score
RaQualia Pharma Inc TSE:4579
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of RaQualia Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3919+0.528 * 1.1167+0.404 * 0.8259+0.892 * 1.2869+0.115 * 0.6517
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0319+4.679 * -0.052346-0.327 * 0.6775
=-2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Dec24) TTM:
Total Receivables was 円1,234 Mil.
Revenue was 801.993 + 0 + 570.563 + 965.409 = 円2,338 Mil.
Gross Profit was 621.093 + 0 + 403.756 + 743.064 = 円1,768 Mil.
Total Current Assets was 円6,482 Mil.
Total Assets was 円11,391 Mil.
Property, Plant and Equipment(Net PPE) was 円439 Mil.
Depreciation, Depletion and Amortization(DDA) was 円349 Mil.
Selling, General, & Admin. Expense(SGA) was 円859 Mil.
Total Current Liabilities was 円1,052 Mil.
Long-Term Debt & Capital Lease Obligation was 円2,191 Mil.
Net Income was -225.693 + 0 + -349.532 + -5.215 = 円-580 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = 円0 Mil.
Cash Flow from Operations was 258.202 + 0 + 57.055 + -299.395 = 円16 Mil.
Total Receivables was 円689 Mil.
Revenue was 0 + 762.467 + 648.581 + 405.709 = 円1,817 Mil.
Gross Profit was 0 + 596.015 + 588.049 + 350.076 = 円1,534 Mil.
Total Current Assets was 円4,539 Mil.
Total Assets was 円9,655 Mil.
Property, Plant and Equipment(Net PPE) was 円529 Mil.
Depreciation, Depletion and Amortization(DDA) was 円214 Mil.
Selling, General, & Admin. Expense(SGA) was 円647 Mil.
Total Current Liabilities was 円1,187 Mil.
Long-Term Debt & Capital Lease Obligation was 円2,870 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1234.479 / 2337.965) / (689.162 / 1816.757)
=0.528014 / 0.379336
=1.3919

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1534.14 / 1816.757) / (1767.913 / 2337.965)
=0.844439 / 0.756176
=1.1167

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6482.198 + 439.187) / 11391.445) / (1 - (4538.963 + 529.084) / 9655.482)
=0.392405 / 0.475112
=0.8259

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2337.965 / 1816.757
=1.2869

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(214.431 / (214.431 + 529.084)) / (348.643 / (348.643 + 439.187))
=0.288402 / 0.442536
=0.6517

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(859.011 / 2337.965) / (646.848 / 1816.757)
=0.367418 / 0.356045
=1.0319

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2190.599 + 1052.467) / 11391.445) / ((2870.057 + 1187.495) / 9655.482)
=0.284693 / 0.420233
=0.6775

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-580.44 - 0 - 15.862) / 11391.445
=-0.052346

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

RaQualia Pharma has a M-score of -2.06 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.06 mean?
RaQualia Pharma (TSE:4579) has a Beneish M-Score of -2.06 as of Jul. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #494 out of 822 companies in the Biotechnology industry, placing it in the top 60.1%.
Is RaQualia Pharma's Beneish M-Score too high?
RaQualia Pharma's current Beneish M-Score is -2.06. Based on the distribution chart, RaQualia Pharma ranks #494 out of 822 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #494 out of 822 companies for Beneish M-Score. This places RaQualia Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current Beneish M-Score is -2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current Beneish M-Score is -2.06. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Beneish M-Score is -2.06 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

  • Beneish M-Score: -2.06
  • GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score

Get the complete analysis for TSE:4579

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円468.00
Price
円961.31
GF Value